| Recruiting | Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host NCT07249346 | Hannah Choe, MD | Phase 2 |
| Recruiting | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880 | Medical College of Wisconsin | N/A |
| Completed | MargheRITA (Remote Intelligence for Therapeutic Adherence) NCT05260203 | Advice Pharma Group srl | N/A |
| Unknown | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic NCT05154474 | Weprom | — |
| Terminated | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB NCT05223699 | Magenta Therapeutics, Inc. | Phase 1 |
| Recruiting | Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune C NCT04800458 | University Hospital, Bordeaux | N/A |
| Active Not Recruiting | ATG Plus PTCy vs ATG for CGVHD Prophylaxis NCT04202835 | McMaster University | Phase 2 |
| Terminated | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS NCT04166929 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 2 |
| Completed | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution NCT03959241 | Medical College of Wisconsin | Phase 3 |
| Active Not Recruiting | Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT NCT04173533 | University of Birmingham | Phase 3 |
| Active Not Recruiting | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients NCT03613727 | Virginia Commonwealth University | Phase 2 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression NCT03480360 | Dartmouth-Hitchcock Medical Center | Phase 3 |
| Active Not Recruiting | Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasi NCT03431090 | Nationwide Children's Hospital | Phase 1 / Phase 2 |
| Completed | Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents NCT03387475 | University Hospital, Grenoble | Phase 2 |
| Withdrawn | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies NCT02765997 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 130 NCT02345850 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 |
| Unknown | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood He NCT02338479 | Center for International Blood and Marrow Transplant Research | — |
| Active Not Recruiting | Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies NCT02323867 | Children's Hospital of Philadelphia | Phase 2 |
| Completed | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Throm NCT01933035 | Beth Israel Medical Center | — |
| Completed | Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant NCT01904175 | Duke University | — |
| Completed | Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation The NCT01956799 | Fondazione Italiana Sindromi Mielodisplastiche-ETS | — |
| Completed | Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations NCT01911871 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia NCT01297543 | Cellerant Therapeutics | Phase 1 / Phase 2 |
| Completed | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) NCT01422603 | University Hospital Southampton NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies NCT01110473 | AbbVie (prior sponsor, Abbott) | Phase 1 |
| Completed | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or R NCT00990587 | University Health Network, Toronto | Phase 1 |
| Completed | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975 | Indiana University School of Medicine | Phase 2 |
| Terminated | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refract NCT00963495 | University Health Network, Toronto | Phase 1 |
| Completed | Sitagliptin Umbilical Cord Blood Transplant Study NCT00862719 | Indiana University School of Medicine | Phase 2 |
| Completed | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia NCT02007863 | University of Miami | N/A |
| Terminated | Decitabine, Cytarabine, GCSF for Refractory AML/MDS NCT00740181 | Brown University | Phase 2 |
| Completed | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant NCT00597714 | David Rizzieri, MD | Phase 2 |
| Completed | Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational No NCT01095874 | Saint-Louis Hospital, Paris, France | — |
| Completed | A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia NCT00580242 | Massachusetts General Hospital | Phase 1 |
| Terminated | In-Vivo Activated T-Cell Depletion to Prevent GVHD NCT00594308 | Indiana University | N/A |
| Terminated | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies NCT00593554 | Sherif S. Farag | Phase 2 |
| Unknown | Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia NCT00434239 | Peter MacCallum Cancer Centre, Australia | EARLY_Phase 1 |
| Completed | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies NCT00506402 | CASI Pharmaceuticals, Inc. | Phase 1 |
| Completed | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants NCT00606437 | Duke University | Phase 1 |
| Terminated | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomono NCT00109538 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath NCT00578942 | David Rizzieri, MD | Phase 2 |
| Completed | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant NCT00354120 | Gruppo Italiano Trapianto di Midollo Osseo | Phase 2 / Phase 3 |
| Terminated | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopo NCT00513318 | University of California, San Francisco | — |
| Completed | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With NCT00145626 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies NCT00795132 | University of Utah | Phase 2 |
| Completed | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath NCT00580034 | David Rizzieri, MD | Phase 2 |
| Completed | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorde NCT00516152 | University of California, San Francisco | Phase 2 |
| Terminated | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies NCT00514722 | University of California, San Francisco | N/A |
| Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematolo NCT00513175 | University of California, San Francisco | — |
| Completed | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patien NCT00195533 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasi NCT00136422 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders NCT00511537 | University of California, San Francisco | — |
| Active Not Recruiting | Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukem NCT00899223 | Alliance for Clinical Trials in Oncology | — |
| Terminated | New York Blood Center National Cord Blood Program NCT00212407 | New York Blood Center | EARLY_Phase 1 |